Physician profile
Gary K Mo
NPI 1366550576
$1,787.62
in general payments reported to CMS, 2019-2025
19 companies · $78.86 in 2025
The $78.86 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $325 · 2021: $395 · 2022: $343 · 2023: $235 · 2024: $115 · 2025: $78.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $420.92 | 2019-2023 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novartis Pharmaceuticals Corporation | $332.48 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $224.36 | 2019-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $152.33 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.12 | 2020-2022 | |
| Boston Scientific Corporation | $71.00 | 2022-2025 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $70.30 | 2019-2022 | |
| Medtronic, INC. | $50.04 | 2023 | Corevalve Evolut R |
| Kiniksa Pharmaceuticals International, Plc | $47.01 | 2024 | Arcalyst |
| Novo Nordisk INC | $46.63 | 2022-2024 | Ozempic, Rybelsus |
| Amgen INC. | $43.83 | 2024-2025 | Repatha |
| Kowa Pharmaceuticals America, INC. | $39.87 | 2020-2021 | |
| Pfizer INC. | $30.87 | 2019-2021 | |
| Abiomed | $25.35 | 2024 | Impella |
| Kiniksa Pharmaceuticals, Ltd. | $24.61 | 2023 | Arcalyst |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $23.78 | 2020-2022 | |
| Medtronic Vascular, INC. | $17.95 | 2019 | |
| Biosense Webster, INC. | $17.66 | 2019 | |
| Irhythm Technologies, INC. | $13.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Mo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.